fashion -WSS

fashion

author：comprehensive 2025-09-06 02:15:28 - browse：79597

DENVER — He could have been a rock star, a religious icon, the way ecstatic applause from thousands of attendees greeted the man dressed in a crisp, all-white suit as he strode onto a backlit stage. He was neither. This was Rick Doblin, the founder and evangelist of a movement to legalize psychedelic MDMA and bring the drug into mainstream medicine.

The scene in a Denver conference hall last week was a world away from the first conference Multidisciplinary Association for Psychedelic Studies (MAPS) held in 1990, when Doblin spoke alongside Timothy Leary — the ex-Harvard professor who popularized the phrase “turn on, tune in, and drop out.” That was just a few years after MDMA, also known as ecstasy, was criminalized, deemed a Schedule 1 drug “of no medical use.”

Now, as MAPS nears its goal of winning Food and Drug Administration approval for MDMA as a treatment for post-traumatic stress disorder, the perpetually smiling and energetic Doblin is basking in the adoration from both legions of “psychonauts” and unlikely yet powerful allies. “I literally love Rick Doblin,” the conservative Republican and former Texas governor Rick Perry told the audience in Denver.

It was a seemingly triumphant occasion. But even as Doblin is in sniffing distance of his lifelong quest, his once counter-cultural organization is grappling with the pressures of having to operate in the capitalist pharmaceutical sphere. MAPS was founded in 1986 as a nonprofit with deep-seated ideals. Doblin developed an “anti-patent” strategy, putting discoveries in the public domain so they couldn’t be claimed as intellectual property. He raised money to fund clinical trials of MDMA from like-minded wealthy donors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： How to keep neuroscience’s past racism from being its future

focus

WSS

3 hurdles to bringing medical devices to the U.S. market

STAT's guide to the next generation of CAR

SEC charges former device maker CEO with $41 million fraud

Why we need to separate burnout from moral injury in health care

HCA sued by state AG for quality issues at Mission Health

CDC concerned about possible undetected monkeypox spread in U.K.

explore

fashion

hotspot

Novavax promises a turnaround & Lilly roils the obesity market

Prime Medicine, Myeloid Therapeutics clash over genome

Apple is now the first public company to be valued at $3 trillion

CDC concerned about possible undetected monkeypox spread in U.K.

Drug repurposing or repositioning? The language matters

New guidelines on severe brain injury complicate already difficult decisions

Heart attack and stroke risk calculators need revising

Do masks work? RCTs can't tell us

Hollywood unions extend contract negotiations for actors

New guidelines on severe brain injury complicate already difficult decisions

Wikipedia

Medicare drug price negotiation hasn't dried up venture capital

WATCH: Why do fingernails fall off when they're damaged?

Do masks work? RCTs can't tell us

Hospitals owned by private equity see complications spike 25%

The strategy behind pharma's lawsuits over drug pricing reform

Why health records don't always know when patients are dead

Wikipedia

focus

focus

explore